BriaCell Reveals Planned Date for Share Consolidation Implementation
Share Consolidation Announcement: BriaCell Therapeutics Corp. has approved a consolidation of its common shares, converting ten pre-Consolidation shares into one post-Consolidation share to comply with Nasdaq listing requirements.
Effective Date and Trading: The consolidation is expected to take effect on August 25, 2025, with the new shares trading under the symbols "BCT" on TSX and "BCTX" on Nasdaq.
Fractional Shares Handling: No fractional shares will be issued; any fractions less than half a share will be canceled, while those equal to or greater than half will be rounded up to a whole share.
Shareholder Instructions: Shareholders will receive instructions for exchanging their shares after the Effective Date, and beneficial holders should contact their intermediaries for processing details.
Trade with 70% Backtested Accuracy
Analyst Views on BCTXZ
No data
About the author
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025
BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.
Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.
Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.
Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.
BriaCell Showcases Strong Anti-Cancer Effects of Bria-OTS+™ at SITC 2025
Bria-OTS+ Platform Overview: BriaCell Therapeutics has showcased its next-generation Bria-OTS+ platform, which demonstrates rapid and durable anti-cancer activity by engaging both innate and adaptive immune responses in preclinical models.
Preclinical Findings: The platform's lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have shown strong immune activation and sustained anti-cancer responses, indicating potential for prolonged clinical benefits.
Broad Applicability: The positive results from Bria-BRES+ and Bria-PROS+ suggest the Bria-OTS+ platform could be expanded to treat other solid tumors, highlighting its ability to generate potent immune responses across various cancer types.
Future Clinical Trials: BriaCell plans to confirm these preclinical findings in upcoming Phase 1/2a clinical studies, with Bria-PROS+ supported by a $2 million National Cancer Institute award.
BriaCell to Showcase Strong Anti-Cancer Effects of Bria-OTS+™ in Breast and Prostate Cancer Studies
Bria-OTS+ Platform Presentation: BriaCell Therapeutics will present its next generation Bria-OTS+ platform, showcasing its strong anti-cancer activity and immune system engagement at the SITC Annual Meeting on November 7, 2025.
Clinical Trials and Funding: The lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have completed GMP manufacturing and are set for clinical trials, with Bria-PROS+ receiving a $2 million NCI SBIR award to support its evaluation.
Innovative Immunotherapy: Bria-OTS+ is an advanced immunotherapy platform designed to enhance immune engagement through multiple immune-activating cytokines and co-stimulatory molecules, building on the positive results of its predecessor, Bria-OTS™.
Company Overview: BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care, with more information available on their website.
BriaCell Expands Clinical Trial Locations for Phase 3 Study on Metastatic Breast Cancer
Clinical Study Enrollment: BriaCell's pivotal Phase 3 study in metastatic breast cancer is enrolling patients at 79 clinical sites across 23 US states, with new additions including Dartmouth Cancer Center and Cedars-Sinai Medical Center.
Study Details: The study evaluates BriaCell's lead candidate, Bria-IMT, in combination with an immune checkpoint inhibitor against physician's choice of treatment, with interim data expected after 144 patient events.
Company's Expectations: BriaCell anticipates that the addition of major cancer centers will accelerate patient enrollment and support their goal of addressing significant unmet medical needs in cancer care.
Regulatory Status: The Bria-IMT combination regimen has received FDA Fast Track designation, and positive results from the study could lead to full approval and marketing authorization for the treatment.
BriaCell Partners with MSK Accelerator to Progress Bria-OTS+™ for Breast Cancer Treatment
Collaboration Announcement: BriaCell Therapeutics Corp. has partnered with Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator Program to enhance the clinical development of its Bria-OTS+ platform, focusing on personalized immunotherapy for various cancers, including metastatic breast cancer.
Support for Clinical Trials: The collaboration will provide BriaCell with manufacturing, IND development, and clinical protocol support for a Phase 1 clinical trial of Bria-BRES+, a personalized immunotherapy targeting breast cancer.
Expertise Access: Through this partnership, BriaCell will leverage MSK's extensive clinical and institutional expertise to expedite the development of its immunotherapy platform, aiming to address significant unmet medical needs in cancer treatment.
Future Potential: Both companies express optimism about the collaboration's potential to transform cancer care and improve patient outcomes through innovative therapeutic approaches.
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025
BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.
Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.
Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.
Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.
BriaCell Showcases Strong Anti-Cancer Effects of Bria-OTS+™ at SITC 2025
Bria-OTS+ Platform Overview: BriaCell Therapeutics has showcased its next-generation Bria-OTS+ platform, which demonstrates rapid and durable anti-cancer activity by engaging both innate and adaptive immune responses in preclinical models.
Preclinical Findings: The platform's lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have shown strong immune activation and sustained anti-cancer responses, indicating potential for prolonged clinical benefits.
Broad Applicability: The positive results from Bria-BRES+ and Bria-PROS+ suggest the Bria-OTS+ platform could be expanded to treat other solid tumors, highlighting its ability to generate potent immune responses across various cancer types.
Future Clinical Trials: BriaCell plans to confirm these preclinical findings in upcoming Phase 1/2a clinical studies, with Bria-PROS+ supported by a $2 million National Cancer Institute award.
BriaCell to Showcase Strong Anti-Cancer Effects of Bria-OTS+™ in Breast and Prostate Cancer Studies
Bria-OTS+ Platform Presentation: BriaCell Therapeutics will present its next generation Bria-OTS+ platform, showcasing its strong anti-cancer activity and immune system engagement at the SITC Annual Meeting on November 7, 2025.
Clinical Trials and Funding: The lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have completed GMP manufacturing and are set for clinical trials, with Bria-PROS+ receiving a $2 million NCI SBIR award to support its evaluation.
Innovative Immunotherapy: Bria-OTS+ is an advanced immunotherapy platform designed to enhance immune engagement through multiple immune-activating cytokines and co-stimulatory molecules, building on the positive results of its predecessor, Bria-OTS™.
Company Overview: BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care, with more information available on their website.
BriaCell Expands Clinical Trial Locations for Phase 3 Study on Metastatic Breast Cancer
Clinical Study Enrollment: BriaCell's pivotal Phase 3 study in metastatic breast cancer is enrolling patients at 79 clinical sites across 23 US states, with new additions including Dartmouth Cancer Center and Cedars-Sinai Medical Center.
Study Details: The study evaluates BriaCell's lead candidate, Bria-IMT, in combination with an immune checkpoint inhibitor against physician's choice of treatment, with interim data expected after 144 patient events.
Company's Expectations: BriaCell anticipates that the addition of major cancer centers will accelerate patient enrollment and support their goal of addressing significant unmet medical needs in cancer care.
Regulatory Status: The Bria-IMT combination regimen has received FDA Fast Track designation, and positive results from the study could lead to full approval and marketing authorization for the treatment.
BriaCell Partners with MSK Accelerator to Progress Bria-OTS+™ for Breast Cancer Treatment
Collaboration Announcement: BriaCell Therapeutics Corp. has partnered with Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator Program to enhance the clinical development of its Bria-OTS+ platform, focusing on personalized immunotherapy for various cancers, including metastatic breast cancer.
Support for Clinical Trials: The collaboration will provide BriaCell with manufacturing, IND development, and clinical protocol support for a Phase 1 clinical trial of Bria-BRES+, a personalized immunotherapy targeting breast cancer.
Expertise Access: Through this partnership, BriaCell will leverage MSK's extensive clinical and institutional expertise to expedite the development of its immunotherapy platform, aiming to address significant unmet medical needs in cancer treatment.
Future Potential: Both companies express optimism about the collaboration's potential to transform cancer care and improve patient outcomes through innovative therapeutic approaches.
